G34 H3K36me3 upregulates MYCN which is selectively targetable by kinases that destabilize the protein. G34 H3K36me3 upregulates MYCN which is selectively.

Slides:

Advertisements

Similar presentations

Effects of MAX reconstitution and of BRG1 depletion in lung cancer cells. Effects of MAX reconstitution and of BRG1 depletion in lung cancer cells. A,

Advertisements

Network protein vulnerability in EGFR TKI‐resistant cells and specific for EGFR‐mutated cells. Network protein vulnerability in EGFR TKI‐resistant cells.

a b SUM149PT Motility Invasion C V C V

Figure 1. IGF2BP1 promotes SRF expression in cancer cells

ETV1 positively regulates KIT expression through direct binding to KIT enhancers in human GIST cells and forms a positive feedback circuit in GIST oncogenesis.

Cytokine-mediated increases in fetal hemoglobin are associated with globin gene histone modification and transcription factor reprogramming by Orapan Sripichai,

Volume 28, Issue 5, Pages (November 2015)

HIS-24 regulates expression of infection-inducible genes.

Volume 138, Issue 2, Pages (February 2010)

Volume 11, Issue 2, Pages (August 2012)

Identification and Validation of Genetic Variants that Influence Transcription Factor and Cell Signaling Protein Levels Ronald J. Hause, Amy L. Stark,

CHK1 downregulation upon ERG overexpression.

G34 induces a transcriptional program linked to forebrain development and self-renewal. G34 induces a transcriptional program linked to forebrain development.

Volume 43, Issue 5, Pages (September 2011)

Volume 7, Issue 6, Pages (June 2014)

Volume 5, Issue 4, Pages e4 (October 2017)

Volume 10, Issue 7, Pages (February 2015)

Volume 1, Issue 2, Pages (February 2012)

Myeloma cell–derived Runx2 promotes myeloma progression in bone

Volume 9, Issue 5, Pages (November 2017)

A genome-wide RNAi pooled screen identifies NF1 as a key determinant of RAF inhibitor sensitivity in melanoma cells. A genome-wide RNAi pooled screen identifies.

Volume 5, Issue 4, Pages e4 (October 2017)

An siRNA screen identifies BER pathway members as sensitizers to temozolomide (TMZ) in pediatric GBM. A and B, SJG2 and KNS42 cells were transfected with.

Alterations in mRNA 3′ UTR Isoform Abundance Accompany Gene Expression Changes in Human Huntington’s Disease Brains Lindsay Romo, Ami Ashar-Patel, Edith.

Volume 14, Issue 5, Pages (February 2016)

Volume 66, Issue 4, Pages e4 (May 2017)

Identification and characterization of a novel KRAS rearrangement in metastatic prostate cancer. Identification and characterization of a novel KRAS rearrangement.

Polycomb Responds to Low Levels of Transcription

Targeted Depletion of Polo-Like Kinase (Plk) 1 Through Lentiviral shRNA or a Small- Molecule Inhibitor Causes Mitotic Catastrophe and Induction of Apoptosis.

Volume 9, Issue 3, Pages (November 2014)

Existence of a nuclear NFATc1–STAT3 complex in pancreatic cancer.

Differential binding of H3K36me3 in G34-mutant KNS42 cells drives pediatric GBM expression signatures. Differential binding of H3K36me3 in G34-mutant KNS42.

A and B, CO-1686–resistant NCI-H1975 cell clones, COR1-1 and COR10-1 display a reduced dependence on EGFR signaling for survival. A and B, CO-1686–resistant.

P300 depletion is lethal in cancer cells harboring loss-of-function mutations in CBP. A, synthetic-lethal effects assessed by colony formation assay. p300.

Volume 15, Issue 12, Pages (June 2016)

Volume 17, Issue 3, Pages (October 2016)

Volume 9, Issue 4, Pages (October 2017)

(A) Western blot probing nuclear extract from wild-type (wt) and the newly generated ACF1 mutant (AcfC) embryos (0–16 h). (A) Western blot probing nuclear.

Volume 41, Issue 2, Pages (January 2011)

MiR-431-5p directly targets RAF1 and is negatively correlated to RAF1 expression (A) The predicted binding sites of miR-431-5p and RAF1 3′-UTR, and mutant.

The CREBBP-modulated network is enriched in signaling pathways upregulated in the light zone (LZ). The CREBBP-modulated network is enriched in signaling.

Pervasive Targeting of Nascent Transcripts by Hfq

Distinct molecular and clinical correlates of H3F3A mutation subgroups

Influence of RdDM on DCL4 Transcript Isoform Expression.

SiRNA screening identifies genes required for the viability of Pim1-ovexpressing prostate cells. siRNA screening identifies genes required for the viability.

EZH2 overexpression establishes a unique and conserved super-enhancer–associated transcriptional landscape. EZH2 overexpression establishes a unique and.

TGF-β1 modulates extracellular matrix–mediated MT1-MMP expression.

Confirmation of candidates from WT1 binding site screen.

The expression of VCX3A and other CT antigens in pediatric HGG

Effect of G9a on the expression of GSH synthesis enzymes.

Pancreatic cancer cell lines are sensitive to knockdown of outlier kinases. Pancreatic cancer cell lines are sensitive to knockdown of outlier kinases.

Transcriptional and genomic targets of EN1 in TNBC cells.

Specific DNA methylation and expression signatures associated with binding of E2A–PBX1 fusion protein. Specific DNA methylation and expression signatures.

RNF2 promotes TGFβ signaling.

Expression pattern of TLR-4 and MyD88 in EOC cells.

A Splicing-Independent Function of SF2/ASF in MicroRNA Processing

DNA demethylation reactivates GSN expression in gastric cancer cells.

Pirh2 represses p73-dependent transactivation.

The effects of HDAC2 knockdown on cell-cycle proteins.

EGFR signaling regulates transcription of PDGFRβ gene.

siRNA screen validation.

Effect of dexamethasone on PCDGF/GP88 mRNA and protein expressions and effect of PCDGF/GP88 on dexamethasone-induced cell death. Effect of dexamethasone.

DDX5 localizes to promoters of DNA replication genes and functions in the loading of RNA polymerase II onto these promoters. DDX5 localizes to promoters.

EZH2-driven lung cancer as a molecularly distinct entity.

Coculture with U937 cells enhances DNMT1 expression in gastric cancer cells. Coculture with U937 cells enhances DNMT1 expression in gastric cancer cells.

Mutant TERT promoter displays active histone marks and distinct long-range interactions: A, cell lines that were used in the study with their origin and.

Synthetic lethality of ROS1 inhibition in E-cadherin–deficient breast tumor cell lines. Synthetic lethality of ROS1 inhibition in E-cadherin–deficient.

KRAS co-mutations are associated with distinct therapeutic vulnerabilities. KRAS co-mutations are associated with distinct therapeutic vulnerabilities.

CREB1 binds at the proximal region of the TGFB2 promoter and induces its transcriptional activation. CREB1 binds at the proximal region of the TGFB2 promoter.

Transcriptional and epigenetic landscapes of RMS cell lines and primary tumors. Transcriptional and epigenetic landscapes of RMS cell lines and primary.

Presentation transcript:

G34 H3K36me3 upregulates MYCN which is selectively targetable by kinases that destabilize the protein. G34 H3K36me3 upregulates MYCN which is selectively targetable by kinases that destabilize the protein. A, ChIP-Seq of H3K36me3 and RNA polymerase II binding for G34-mutant KNS42 (blue) and wild-type (wt) SF188 cells (gray) for the MYCN locus, which also encompasses the MYCNOS transcript. B, validation of ChIP-Seq data by ChIP-qPCR using specific primers targeting MYCN. Blue bars, KNS42; gray, SF188. ***, P < 0.0001, t test. C, boxplot of MYCN expression in the integrated pediatric GBM samples stratified by H3F3A status. Blue box, G34; green, K27; gray, wild-type. **, P < 0.01, ANOVA. Wild-type tumors with high mRNA expression were frequently amplified (Amp). D, top, immunohistochemistry for MYCN protein in a G34-mutant pediatric GBM sample. RMH2465 bottom, barplot of MYCN expression in a pediatric GBM tissue microarray stratified by H3F3A status. Blue bars, G34; green, K27; gray, wild-type. ++, strong expression; +, moderate expression; −, negative. E, effects on cell viability of MYCN knockdown in KNS42 cells. Western blot analysis showing efficiency of reduction of MYCN by 3 individual siRNAs targeting MYCN (named 6, 12, and W) and a pool of all 3 after 48 and 96 hours. Barplot showing effects on KNS42 cell viability after siRNA knockdown at 7 days. ***, P < 0.001, t test versus control. F, siRNA screen for 714 human kinases in KNS42 cells. Western blot analysis showing expression of MYCN protein in G34-mutant KNS42 cells in contrast to a panel of wild-type pediatric glioma lines. GAPDH is used as a loading control. Kinase targets are plotted in plate well order along the x-axis, and Z scores along the y-axis. PLK1 is used as a positive control and is plotted in red. Negative controls are colored light gray, and kinases with Z scores greater than −2.0 (no effect on cell viability) are colored gray. “Hits” (Z score < −2.0) are colored dark gray or blue, the latter if the effect on cell viability is specific to KNS42 cells and not in a panel of 4 H3F3A wild-type pediatric glioma cell lines. The most significant and selective hits were for CHK1 and AURKA. G, effect of knockdown of AURKA on MYCN levels in KNS42 cells. Western blot analysis for AURKA and MYCN in KNS42 cells treated with individual oligonucleotides directed against AURKA for 48 and 96 hours. GAPDH is used as a loading control. H, effect of a selective small-molecule inhibitor of AURKA on MYCN protein levels and cell viability. Left, Western blot analysis for MYCN protein in KNS42 cells after exposure to 0.1, 0.5, and 2 to 5 μmol/L VX-689 (triangle). GAPDH is used as a loading control. Right, barplot showing effects on cell viability of KNS42 cells exposed to 0.1, 0.5, and 2 to 5 μmol/L VX-689. **, P < 0.01, t test versus control. Lynn Bjerke et al. Cancer Discovery 2013;3:512-519 ©2013 by American Association for Cancer Research